Loading…
Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
Purpose In the phase III EMILIA study, trastuzumab emtansine (T-DM1) significantly improved progression-free survival (PFS) and overall survival (OS) versus capecitabine plus lapatinib (control) in previously treated human epidermal growth factor receptor 2-positive advanced breast cancer. Using EMI...
Saved in:
| Published in: | Cancer chemotherapy and pharmacology 2017-12, Vol.80 (6), p.1079-1090 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c372t-ff836c030580a4484af97762a9b5eb1efcbd669d8b85869950a39dbccd3269593 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c372t-ff836c030580a4484af97762a9b5eb1efcbd669d8b85869950a39dbccd3269593 |
| container_end_page | 1090 |
| container_issue | 6 |
| container_start_page | 1079 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 80 |
| creator | Li, Chunze Wang, Bei Chen, Shang-Chiung Wada, Russell Lu, Dan Wang, Xin Polhamus, Daniel French, Jonathan Vadhavkar, Shweta Strasak, Alexander Smitt, Melanie Joshi, Amita Samant, Meghna Quartino, Angelica Jin, Jin Girish, Sandhya |
| description | Purpose
In the phase III EMILIA study, trastuzumab emtansine (T-DM1) significantly improved progression-free survival (PFS) and overall survival (OS) versus capecitabine plus lapatinib (control) in previously treated human epidermal growth factor receptor 2-positive advanced breast cancer. Using EMILIA data, we evaluated the T-DM1 exposure–response relationship.
Methods
Exposure–response relationships were examined with four exposure metrics [model-predicted and observed minimum concentration (
C
min
) and area under the concentration–time curve from time zero to day 21 of T-DM1 at cycle 1] and multiple efficacy (OS, PFS, objective response rate) and safety (grade ≥ 3 adverse events, grade ≥ 3 thrombocytopenia, grade ≥ 3 hepatotoxicity) endpoints.
Results
An apparent exposure–response trend was observed between model-predicted exposure metrics and efficacy; trends for observed exposure metrics were shallower and often not significant. Although median OS and PFS were numerically longer in patients with higher versus lower model-predicted cycle 1
C
min
, OS and PFS hazard ratios for T-DM1-treated patients in the lowest exposure quartile (
Q
1) versus control were |
| doi_str_mv | 10.1007/s00280-017-3440-4 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1963842622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1963842622</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-ff836c030580a4484af97762a9b5eb1efcbd669d8b85869950a39dbccd3269593</originalsourceid><addsrcrecordid>eNp1kc1u1DAURi1URIfCA3SDLHVtuP5JYi9RNVCkSkgI1paT3ECqGSf4OkOHFe_AlqfjSfAwLeqGlWX7fOdK92PsXMJLCdC8IgBlQYBshDYGhHnEVtJoJcAafcJWUF5F1YA5ZU-JbgDASK2fsFPlQKkCrdiv9e080ZLw94-fCWmeIiEPMWz2hMSngecUKC_fl21oOW5ziDRG5GPkc8gjxkz825i_8Kv1ByWKaczjrgj6XYgd9rxNWOK8O9wSnxPuxmmhzb5oMeQC_A0_nBFizwPP4TZEfMYeD2FD-PzuPGOf3qw_Xl6J6_dv312-vhadblQWw2B13YGGykIwxpowuKapVXBtha3EoWv7una9bW1la-cqCNr1bdf1WtWucvqMXRy9c5q-LkjZ30xLKksgL12trVG1UoWSR6pLE1HCwc9p3Ia09xL8oQ9_7MOXPvyhD29K5sWdeWm32P9L3BdQAHUEqHzFz5gejP6v9Q-t75pG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1963842622</pqid></control><display><type>article</type><title>Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane</title><source>Springer Link</source><creator>Li, Chunze ; Wang, Bei ; Chen, Shang-Chiung ; Wada, Russell ; Lu, Dan ; Wang, Xin ; Polhamus, Daniel ; French, Jonathan ; Vadhavkar, Shweta ; Strasak, Alexander ; Smitt, Melanie ; Joshi, Amita ; Samant, Meghna ; Quartino, Angelica ; Jin, Jin ; Girish, Sandhya</creator><creatorcontrib>Li, Chunze ; Wang, Bei ; Chen, Shang-Chiung ; Wada, Russell ; Lu, Dan ; Wang, Xin ; Polhamus, Daniel ; French, Jonathan ; Vadhavkar, Shweta ; Strasak, Alexander ; Smitt, Melanie ; Joshi, Amita ; Samant, Meghna ; Quartino, Angelica ; Jin, Jin ; Girish, Sandhya</creatorcontrib><description>Purpose
In the phase III EMILIA study, trastuzumab emtansine (T-DM1) significantly improved progression-free survival (PFS) and overall survival (OS) versus capecitabine plus lapatinib (control) in previously treated human epidermal growth factor receptor 2-positive advanced breast cancer. Using EMILIA data, we evaluated the T-DM1 exposure–response relationship.
Methods
Exposure–response relationships were examined with four exposure metrics [model-predicted and observed minimum concentration (
C
min
) and area under the concentration–time curve from time zero to day 21 of T-DM1 at cycle 1] and multiple efficacy (OS, PFS, objective response rate) and safety (grade ≥ 3 adverse events, grade ≥ 3 thrombocytopenia, grade ≥ 3 hepatotoxicity) endpoints.
Results
An apparent exposure–response trend was observed between model-predicted exposure metrics and efficacy; trends for observed exposure metrics were shallower and often not significant. Although median OS and PFS were numerically longer in patients with higher versus lower model-predicted cycle 1
C
min
, OS and PFS hazard ratios for T-DM1-treated patients in the lowest exposure quartile (
Q
1) versus control were < 1 after adjusting for baseline risk factors (e.g., ECOG status, tumor burden, measurable disease, and number of disease sites). No meaningful exposure–response relationship was observed for any safety endpoints.
Conclusion
Exposure–response relationships for efficacy were inconsistent across exposure metrics; model-predicted cycle 1
C
min
showed the strongest exposure–response trend. The
Q
1 subgroup based on model-predicted cycle 1
C
min
had numerically similar or better OS and PFS versus control following covariate adjustment. The approved T-DM1 dose (3.6 mg/kg every 3 weeks) has a positive benefit–risk ratio versus control, even for the T-DM1
Q
1 subgroup.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-017-3440-4</identifier><identifier>PMID: 29022084</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antineoplastic Agents, Immunological - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Bridged-Ring Compounds - therapeutic use ; Cancer ; Cancer Research ; Effectiveness ; Epidermal growth factor ; ErbB-2 protein ; Exposure ; Female ; Hepatotoxicity ; Humans ; Immunotherapy ; Maytansine - analogs & derivatives ; Maytansine - therapeutic use ; Medicine ; Medicine & Public Health ; Middle Aged ; Monoclonal antibodies ; Numerical prediction ; Oncology ; Original Article ; Patients ; Pharmacology/Toxicology ; Quality ; Receptor, ErbB-2 - metabolism ; Risk analysis ; Risk factors ; Risk management ; Survival ; Targeted cancer therapy ; Taxanes ; Taxoids - therapeutic use ; Thrombocytopenia ; Trastuzumab ; Trastuzumab - therapeutic use ; Trends</subject><ispartof>Cancer chemotherapy and pharmacology, 2017-12, Vol.80 (6), p.1079-1090</ispartof><rights>Springer-Verlag GmbH Germany 2017</rights><rights>Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-ff836c030580a4484af97762a9b5eb1efcbd669d8b85869950a39dbccd3269593</citedby><cites>FETCH-LOGICAL-c372t-ff836c030580a4484af97762a9b5eb1efcbd669d8b85869950a39dbccd3269593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29022084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Chunze</creatorcontrib><creatorcontrib>Wang, Bei</creatorcontrib><creatorcontrib>Chen, Shang-Chiung</creatorcontrib><creatorcontrib>Wada, Russell</creatorcontrib><creatorcontrib>Lu, Dan</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Polhamus, Daniel</creatorcontrib><creatorcontrib>French, Jonathan</creatorcontrib><creatorcontrib>Vadhavkar, Shweta</creatorcontrib><creatorcontrib>Strasak, Alexander</creatorcontrib><creatorcontrib>Smitt, Melanie</creatorcontrib><creatorcontrib>Joshi, Amita</creatorcontrib><creatorcontrib>Samant, Meghna</creatorcontrib><creatorcontrib>Quartino, Angelica</creatorcontrib><creatorcontrib>Jin, Jin</creatorcontrib><creatorcontrib>Girish, Sandhya</creatorcontrib><title>Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose
In the phase III EMILIA study, trastuzumab emtansine (T-DM1) significantly improved progression-free survival (PFS) and overall survival (OS) versus capecitabine plus lapatinib (control) in previously treated human epidermal growth factor receptor 2-positive advanced breast cancer. Using EMILIA data, we evaluated the T-DM1 exposure–response relationship.
Methods
Exposure–response relationships were examined with four exposure metrics [model-predicted and observed minimum concentration (
C
min
) and area under the concentration–time curve from time zero to day 21 of T-DM1 at cycle 1] and multiple efficacy (OS, PFS, objective response rate) and safety (grade ≥ 3 adverse events, grade ≥ 3 thrombocytopenia, grade ≥ 3 hepatotoxicity) endpoints.
Results
An apparent exposure–response trend was observed between model-predicted exposure metrics and efficacy; trends for observed exposure metrics were shallower and often not significant. Although median OS and PFS were numerically longer in patients with higher versus lower model-predicted cycle 1
C
min
, OS and PFS hazard ratios for T-DM1-treated patients in the lowest exposure quartile (
Q
1) versus control were < 1 after adjusting for baseline risk factors (e.g., ECOG status, tumor burden, measurable disease, and number of disease sites). No meaningful exposure–response relationship was observed for any safety endpoints.
Conclusion
Exposure–response relationships for efficacy were inconsistent across exposure metrics; model-predicted cycle 1
C
min
showed the strongest exposure–response trend. The
Q
1 subgroup based on model-predicted cycle 1
C
min
had numerically similar or better OS and PFS versus control following covariate adjustment. The approved T-DM1 dose (3.6 mg/kg every 3 weeks) has a positive benefit–risk ratio versus control, even for the T-DM1
Q
1 subgroup.</description><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Bridged-Ring Compounds - therapeutic use</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Effectiveness</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Exposure</subject><subject>Female</subject><subject>Hepatotoxicity</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Maytansine - analogs & derivatives</subject><subject>Maytansine - therapeutic use</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Numerical prediction</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Pharmacology/Toxicology</subject><subject>Quality</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Risk management</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Taxanes</subject><subject>Taxoids - therapeutic use</subject><subject>Thrombocytopenia</subject><subject>Trastuzumab</subject><subject>Trastuzumab - therapeutic use</subject><subject>Trends</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1DAURi1URIfCA3SDLHVtuP5JYi9RNVCkSkgI1paT3ECqGSf4OkOHFe_AlqfjSfAwLeqGlWX7fOdK92PsXMJLCdC8IgBlQYBshDYGhHnEVtJoJcAafcJWUF5F1YA5ZU-JbgDASK2fsFPlQKkCrdiv9e080ZLw94-fCWmeIiEPMWz2hMSngecUKC_fl21oOW5ziDRG5GPkc8gjxkz825i_8Kv1ByWKaczjrgj6XYgd9rxNWOK8O9wSnxPuxmmhzb5oMeQC_A0_nBFizwPP4TZEfMYeD2FD-PzuPGOf3qw_Xl6J6_dv312-vhadblQWw2B13YGGykIwxpowuKapVXBtha3EoWv7una9bW1la-cqCNr1bdf1WtWucvqMXRy9c5q-LkjZ30xLKksgL12trVG1UoWSR6pLE1HCwc9p3Ia09xL8oQ9_7MOXPvyhD29K5sWdeWm32P9L3BdQAHUEqHzFz5gejP6v9Q-t75pG</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Li, Chunze</creator><creator>Wang, Bei</creator><creator>Chen, Shang-Chiung</creator><creator>Wada, Russell</creator><creator>Lu, Dan</creator><creator>Wang, Xin</creator><creator>Polhamus, Daniel</creator><creator>French, Jonathan</creator><creator>Vadhavkar, Shweta</creator><creator>Strasak, Alexander</creator><creator>Smitt, Melanie</creator><creator>Joshi, Amita</creator><creator>Samant, Meghna</creator><creator>Quartino, Angelica</creator><creator>Jin, Jin</creator><creator>Girish, Sandhya</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20171201</creationdate><title>Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane</title><author>Li, Chunze ; Wang, Bei ; Chen, Shang-Chiung ; Wada, Russell ; Lu, Dan ; Wang, Xin ; Polhamus, Daniel ; French, Jonathan ; Vadhavkar, Shweta ; Strasak, Alexander ; Smitt, Melanie ; Joshi, Amita ; Samant, Meghna ; Quartino, Angelica ; Jin, Jin ; Girish, Sandhya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-ff836c030580a4484af97762a9b5eb1efcbd669d8b85869950a39dbccd3269593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Bridged-Ring Compounds - therapeutic use</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Effectiveness</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Exposure</topic><topic>Female</topic><topic>Hepatotoxicity</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Maytansine - analogs & derivatives</topic><topic>Maytansine - therapeutic use</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Numerical prediction</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Pharmacology/Toxicology</topic><topic>Quality</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Risk management</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Taxanes</topic><topic>Taxoids - therapeutic use</topic><topic>Thrombocytopenia</topic><topic>Trastuzumab</topic><topic>Trastuzumab - therapeutic use</topic><topic>Trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Chunze</creatorcontrib><creatorcontrib>Wang, Bei</creatorcontrib><creatorcontrib>Chen, Shang-Chiung</creatorcontrib><creatorcontrib>Wada, Russell</creatorcontrib><creatorcontrib>Lu, Dan</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Polhamus, Daniel</creatorcontrib><creatorcontrib>French, Jonathan</creatorcontrib><creatorcontrib>Vadhavkar, Shweta</creatorcontrib><creatorcontrib>Strasak, Alexander</creatorcontrib><creatorcontrib>Smitt, Melanie</creatorcontrib><creatorcontrib>Joshi, Amita</creatorcontrib><creatorcontrib>Samant, Meghna</creatorcontrib><creatorcontrib>Quartino, Angelica</creatorcontrib><creatorcontrib>Jin, Jin</creatorcontrib><creatorcontrib>Girish, Sandhya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Chunze</au><au>Wang, Bei</au><au>Chen, Shang-Chiung</au><au>Wada, Russell</au><au>Lu, Dan</au><au>Wang, Xin</au><au>Polhamus, Daniel</au><au>French, Jonathan</au><au>Vadhavkar, Shweta</au><au>Strasak, Alexander</au><au>Smitt, Melanie</au><au>Joshi, Amita</au><au>Samant, Meghna</au><au>Quartino, Angelica</au><au>Jin, Jin</au><au>Girish, Sandhya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>80</volume><issue>6</issue><spage>1079</spage><epage>1090</epage><pages>1079-1090</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Purpose
In the phase III EMILIA study, trastuzumab emtansine (T-DM1) significantly improved progression-free survival (PFS) and overall survival (OS) versus capecitabine plus lapatinib (control) in previously treated human epidermal growth factor receptor 2-positive advanced breast cancer. Using EMILIA data, we evaluated the T-DM1 exposure–response relationship.
Methods
Exposure–response relationships were examined with four exposure metrics [model-predicted and observed minimum concentration (
C
min
) and area under the concentration–time curve from time zero to day 21 of T-DM1 at cycle 1] and multiple efficacy (OS, PFS, objective response rate) and safety (grade ≥ 3 adverse events, grade ≥ 3 thrombocytopenia, grade ≥ 3 hepatotoxicity) endpoints.
Results
An apparent exposure–response trend was observed between model-predicted exposure metrics and efficacy; trends for observed exposure metrics were shallower and often not significant. Although median OS and PFS were numerically longer in patients with higher versus lower model-predicted cycle 1
C
min
, OS and PFS hazard ratios for T-DM1-treated patients in the lowest exposure quartile (
Q
1) versus control were < 1 after adjusting for baseline risk factors (e.g., ECOG status, tumor burden, measurable disease, and number of disease sites). No meaningful exposure–response relationship was observed for any safety endpoints.
Conclusion
Exposure–response relationships for efficacy were inconsistent across exposure metrics; model-predicted cycle 1
C
min
showed the strongest exposure–response trend. The
Q
1 subgroup based on model-predicted cycle 1
C
min
had numerically similar or better OS and PFS versus control following covariate adjustment. The approved T-DM1 dose (3.6 mg/kg every 3 weeks) has a positive benefit–risk ratio versus control, even for the T-DM1
Q
1 subgroup.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29022084</pmid><doi>10.1007/s00280-017-3440-4</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2017-12, Vol.80 (6), p.1079-1090 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_1963842622 |
| source | Springer Link |
| subjects | Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Bridged-Ring Compounds - therapeutic use Cancer Cancer Research Effectiveness Epidermal growth factor ErbB-2 protein Exposure Female Hepatotoxicity Humans Immunotherapy Maytansine - analogs & derivatives Maytansine - therapeutic use Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Numerical prediction Oncology Original Article Patients Pharmacology/Toxicology Quality Receptor, ErbB-2 - metabolism Risk analysis Risk factors Risk management Survival Targeted cancer therapy Taxanes Taxoids - therapeutic use Thrombocytopenia Trastuzumab Trastuzumab - therapeutic use Trends |
| title | Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T13%3A00%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exposure%E2%80%93response%20analyses%20of%20trastuzumab%20emtansine%20in%20patients%20with%20HER2-positive%20advanced%20breast%20cancer%20previously%20treated%20with%20trastuzumab%20and%20a%20taxane&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Li,%20Chunze&rft.date=2017-12-01&rft.volume=80&rft.issue=6&rft.spage=1079&rft.epage=1090&rft.pages=1079-1090&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-017-3440-4&rft_dat=%3Cproquest_cross%3E1963842622%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c372t-ff836c030580a4484af97762a9b5eb1efcbd669d8b85869950a39dbccd3269593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1963842622&rft_id=info:pmid/29022084&rfr_iscdi=true |